Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI
Author(s) -
Benjamin C. Blount,
Mateusz P. Karwowski,
Peter G. Shields,
Maria Morel-Espinosa,
Liza Valentín-Blasini,
Michael Gardner,
Martha Braselton,
Christina R. Brosius,
Kevin T. Caron,
David M. Chambers,
Joseph Corstvet,
Elizabeth A. Cowan,
Víctor R. De Jesús,
Paul Espinosa,
Carolina Fernández,
Cory Holder,
Zsuzsanna Kuklenyik,
Jennifer D. Kusovschi,
Cody A. Newman,
Gregory B. Reis,
Jon Rees,
C. C. Reese,
Lalith Silva,
Tiffany Seyler,
MinAe Song,
Connie S. Sosnoff,
Carleen R. Spitzer,
Denise S. Tevis,
Lanqing Wang,
Cliff Watson,
Mark D. Wewers,
Baoyun Xia,
Douglas T. Heitkemper,
Isaac Ghinai,
Jennifer E. Layden,
Peter A. Briss,
Brian A. King,
Lisa Delaney,
Christopher M. Jones,
Grant Baldwin,
Anita Patel,
Dana MeaneyDelman,
Dale A. Rose,
Vikram Krishnasamy,
John R. Barr,
Jerry Thomas,
James L. Pirkle
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1916433
Subject(s) - bronchoalveolar lavage , medicine , lung , immunology
The causative agents for the current national outbreak of electronic-cigarette, or vaping, product use-associated lung injury (EVALI) have not been established. Detection of toxicants in bronchoalveolar-lavage (BAL) fluid from patients with EVALI can provide direct information on exposure within the lung.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom